Cassava SciencesSAVA
SAVA
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
26% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 35
6.87% more ownership
Funds ownership: 29.27% [Q3] → 36.13% (+6.87%) [Q4]
14% less funds holding
Funds holding: 160 [Q3] → 137 (-23) [Q4]
38% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 52
63% less call options, than puts
Call options by funds: $10.1M | Put options by funds: $27.2M
87% less capital invested
Capital invested by funds: $412M [Q3] → $51.8M (-$360M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2
18%
upside
Avg. target
$2
18%
upside
High target
$2
18%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Vernon Bernardino 24% 1-year accuracy 16 / 67 met price target | 18%upside $2 | Neutral Reiterated | 25 Mar 2025 |
Financial journalist opinion
Based on 6 articles about SAVA published over the past 30 days
Negative
Reuters
1 day ago
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon-to-be-discontinued Alzheimer's drug simufilam.

Negative
Zacks Investment Research
2 days ago
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.

Negative
Benzinga
2 days ago
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Cassava Sciences Inc. SAVA on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer's disease.

Neutral
GlobeNewsWire
3 days ago
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for central nervous system disorders, including Alzheimer's disease (AD) dementia and tuberous sclerosis complex (TSC)-related epilepsy, today shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD.

Positive
Zacks Investment Research
2 weeks ago
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?
Cassava Sciences (SAVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Neutral
GlobeNewsWire
3 weeks ago
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, including Alzheimer's disease and tuberous sclerosis complex (TSC)-related seizures, today reported financial results for the year ended December 31, 2024 and provided a business update.

Neutral
Accesswire
1 month ago
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128597&wire=1 or contact Joseph E. Levi, Esq.

Neutral
Accesswire
1 month ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128562&wire=1 or contact Joseph E. Levi, Esq.

Neutral
Accesswire
1 month ago
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128534&wire=1 or contact Joseph E. Levi, Esq.

Neutral
Accesswire
1 month ago
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128502&wire=1 or contact Joseph E. Levi, Esq.

Charts implemented using Lightweight Charts™